Skip to main content
SpringerLink
Log in

Preventive Therapy for Tuberculosis

  • Chapter
Mycobacteria

Part of the book series: Chapman & Hall Medical Microbiology Series ((CHMMS))

  • 142 Accesses

Abstract

Most individuals infected by Mycobacterium tuberculosis do not immediately develop disease, and the interval between infection and illness can range from months to decades. The development of infectious, pulmonary tuberculosis, epidemiologically the most important form of disease because it is the source transmission and new infections, is usually the result of the reactivation of such a latent infection. This period of latency provides an opportunity for secondary prevention of tuberculosis. This strategy takes on increasing importance as the risk of infection with M. tuberculosis in a community decreases and the proportion of incident cases resulting from reactivation of old infections increases. Secondary prevention also takes on an increasing clinical importance as evidence increases that the development of active tuberculosis in persons also infected with HIV increases the speed of progression of the HIV infection. The concept of preventive therapy for tuberculin-positive individuals developed along with isoniazid and preventive therapy with isoniazid has become a central part of the national tuberculosis control program in the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lincoln EM (1954) The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc 69(5):682–689.

    PubMed  CAS  Google Scholar 

  2. Zorini AO (1958) Antituberculous chemoprophylaxis with isoniazid: preliminary note. Dis Chest 32(1):1–17.

    Article  Google Scholar 

  3. Debre R, Perdrizet S, Lotte A, Naveau M, Lert F (1973) Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969. Int J Epidem 2:153–160.

    Article  CAS  Google Scholar 

  4. Ferebee SH, Mount FW (1962) Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 85(4):490–521.

    PubMed  CAS  Google Scholar 

  5. Ferebee SH (1969) Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 17:28–106.

    Google Scholar 

  6. Comstock GW, Baum C, Snider DE (1979) Isoniazid prophylaxis among Alaskan eskimos: A final report of the Bethel isoniazid studies. Am Rev Respir Dis 119(5):827–830.

    PubMed  CAS  Google Scholar 

  7. International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull WHO 60:555–564.

    Google Scholar 

  8. Hsu KHK (1974) Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children. J. Amer. Med. Assoc. 229:528–533.

    Article  CAS  Google Scholar 

  9. Hsu KHK (1984) Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents. J. Amer. Med. Assoc. 251:1283–1285.

    Article  CAS  Google Scholar 

  10. Rieder HL, Cauthen GM, Comstock GW, Snider DE Jr (1989) Epidemiology of tuberculosis in the United States Epidemiol Rev 11:79–98.

    CAS  Google Scholar 

  11. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein R, Walker AT, Friendland GH (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320:545–550.

    Article  PubMed  CAS  Google Scholar 

  12. DiPerri G, Danzi MC, DeChecchi G, Pizzighella S, Solbiati M, Cruciani M, Luzzati R, Malena M, Mazzi R, Concia E, Bassetti D (1989) Lancet 8678:1502–1504.

    Google Scholar 

  13. Centers for Disease Control and Prevention (CDC) (1991) Tuberculosis outbreak among persons in a residential facility for HIV infected persons-San Francisco. 40: 649–652.

    Google Scholar 

  14. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE (1992) High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. J Am Med Assoc 268:504–509.

    Article  CAS  Google Scholar 

  15. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr (1993) Effect of isoniazid prophylaxis on incidence of active tuberculosis and progress of HIV infection. Lancet 342:268–272.

    Article  PubMed  CAS  Google Scholar 

  16. Halsey N, Coberly J, Atkinson J, Boulos R (1994) Twice weekly INH for TB prophylaxis. In: X International Conference on AIDS. Yokohama, abstract No. PB0681.

    Google Scholar 

  17. Wadhawan D, Hira S, Mwansa N, Sunkutu R, Adera T, Perine P (1993) Preventive tuberculosis chemotherapy with isoniazid (INH) among patients infected with HIV1. In: IX International Conference on AIDS, abstract No. PO-B07–1114.

    Google Scholar 

  18. Whalen C, Horsburgh CR, Horm D, Lahart C, Simberkoff M, Ellner J (1995) Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151:129–135.

    PubMed  CAS  Google Scholar 

  19. Pitts FW (1977) Tuberculosis prevention and therapy. In: Hook EW, Mandel GL, Gwatney JM Jr, eds. Current Concepts in Infectious Diseases, pp. 181–194. New York: John Wiley and Sons.

    Google Scholar 

  20. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD (1976) Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 84:181–192.

    PubMed  CAS  Google Scholar 

  21. Kopanoff DE, Snider DE Jr, Caras GJ (1978) Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117(6):991–1001.

    PubMed  CAS  Google Scholar 

  22. Dash LA, Comstock GW, Flynn JPG (1980) Isoniazid preventive therapy retrospect and prospect. Am Rev Respir Dis 121:1039–1044.

    PubMed  CAS  Google Scholar 

  23. Colice GL, Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med 150:2517–2522.

    Google Scholar 

  24. Rose DN, Schecter CB, Fahs MC, Silver AL (1988) Tuberculosis prevention: Costeffectiveness analysis of isoniazid chemoprophylaxis. Am J Prevent Med 4:102–109.

    CAS  Google Scholar 

  25. Taylor WC, Aronson MD, Delbanco TL (1981) Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med 94:808–813.

    PubMed  CAS  Google Scholar 

  26. Tsevat J, Taylor WC, Wong JB, Pauker SG (1988) Isoniazid for the tuberculin reactor: Take it or leave it. Am Rev Respir Dis 137:215–220.

    Article  PubMed  CAS  Google Scholar 

  27. Snider DE Jr, Caras GJ (1992) Isoniazid-associated hepatitis deaths: A review of available information. Am Rev Respir Dis 145:494–497.

    PubMed  Google Scholar 

  28. American Thoracic Society and the Centers for Disease Control and Prevention (1994) Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Crit Care Med 149:1359–1374.

    Google Scholar 

  29. Centers for Disease Control and Prevention (1995) Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. Morbid Mortal Wkly Rep 44(RR-11):19–34.

    Google Scholar 

  30. Centers for Disease Control (1991) Purified protein derivative (PPD)-tuberculin anergy and HIV infection: Guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morbid Mortal Wkly Rep 40(RR-5):27–33.

    Google Scholar 

  31. Jordan TJ, Lewit EM, Montgomery RL, Reichman LB (1991) Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. J Am Med Assoc 265(22):2987— 2991.

    Article  CAS  Google Scholar 

  32. Snider DE Jr, Caras GJ, Koplan JP (1986) Preventive therapy with isoniazid: Costeffective of different durations of therapy. J Am Med Assoc 255:1579–1583.

    Article  Google Scholar 

  33. American Academy of Pediatrics (1991) Report of the Committee on Infectious Diseases, 22nd ed., pp. 487–508. Elk Grove, IL: American Academy of Pediatrics.

    Google Scholar 

  34. Kaplan JE, Masur H, Holmes KK, McNeil MM, Schonberger LB, Navin TR, Hanson DL, Gross PA, Jaffe HW, and the USPHS/IDSA Prevention of Opportunistic Infections Working Group (1995) USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Disease specific recommendations. Clin Infect Dis 21(Suppl 1):S32—S43.

    Article  Google Scholar 

  35. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council (1989) A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear negative pulmonary tuberculosis. Results at 5 years. Am Rev Respir Dis 139:871–876.

    Google Scholar 

  36. Dutt AK, Moers D, Stead WW (1989) Smear- and culture-negative pulmonary tuberculosis: four-month short course chemotherapy. Am Rev Respir Dis 139:867— 870.

    PubMed  CAS  Google Scholar 

  37. International Union Against Tuberculosis and Lung Disease (1994) Tuberculosis Guide for Low Income Countries, 3rd ed. Paris: IUATLD.

    Google Scholar 

  38. World Health Organization (1993) Treatment of Tuberculosis: Guidelines for National Programmes. Geneva: World Health Organization.

    Google Scholar 

  39. World Health Organization and the International Union Against Tuberculosis and Lung Disease (1994) Tuberculosis preventive therapy in HIV-infected individuals. WHO Wkly Epidemiol Rec 68:361–364.

    Google Scholar 

  40. Aisu T, Raviglione MC, van Praag E, Eriki E, Narain J, Barugahare L, Tembo G, McFarland D, Adatu Engwau F (1995) Preventive chemotherapy for HIV-associated tuberculosis in Uganda; an operational assessment at a voluntary counseling and testing centre. AIDS 9:267–273.

    PubMed  CAS  Google Scholar 

  41. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council (1992) A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 145:36–41.

    Article  Google Scholar 

  42. Centers for Disease Control (1992) Recommendations for the management of persons exposed to multidrug-resistant tuberculosis. Morbid Mortal Wkly Rep 41(RR-11):59.

    Google Scholar 

  43. Geiter LJ, O’Brien RJ (1987) Conference on new approaches for tuberculosis preventive therapy. Journal of Infectious Diseases (JID) 156(3):536–537.

    Article  CAS  Google Scholar 

  44. Lecoeur HF, Truffot-Pernot C, Grosset JH (1989) Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140:1189–1193.

    Article  PubMed  CAS  Google Scholar 

  45. Geiter LJ, O’Brien RJ, Kopanoff DE (1990) Short-course preventive therapy. Am Rev Respir Dis 141(4, part 2):A437.

    Google Scholar 

  46. Magdorf K, Arizzi-Rusche AF, Geiter LJ, O’Brien RJ, Wahn U (1991) Short-course preventive therapy for tuberculosis: a pilot study of rifampin and rifampinpyrazinamide regimens in children (abstract). Am Rev Respir Dis 143(4, part 2):A119.

    Google Scholar 

  47. Grazcyk J, O’Brien RJ, Bek E, Nimerowska H, Geiter LJ (1991) Assessment of rifampin containing regimens for tuberculosis preventive therapy: preliminary results of a pilot study in Poland (abstract). Am Rev Respir Dis 143(4, part 2):A 119.

    Google Scholar 

Download references

Authors
  1. Lawrence J. Geiter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chicago College of Medicine, University of Illinois, Chicago, Illinois, USA

    Pattisapu R. J. Gangadharam Ph.D. (Professor of Medicine, Microbiology, and Pathology, Director of Mycobacteriology Research) (Professor of Medicine, Microbiology, and Pathology, Director of Mycobacteriology Research)

  2. Public Health Laboratory Service, University Hospital of Wales, UK

    P. Anthony Jenkins Ph.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Geiter, L.J. (1998). Preventive Therapy for Tuberculosis. In: Gangadharam, P.R.J., Jenkins, P.A. (eds) Mycobacteria. Chapman & Hall Medical Microbiology Series. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-7511-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-7511-5_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4615-7513-9

  • Online ISBN: 978-1-4615-7511-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation